UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934







Date of Report: May       09, 2016

(Date of earliest event reported)




Theravance Biopharma, Inc.

(Exact name of registrant as specified in its charter)





Cayman Islands

(State or other jurisdiction 
of incorporation)


001-36033

(Commission File Number)


EIN 98-1226628

(IRS Employer 
Identification Number)






PO Box 309, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands 

(Address of principal executive offices)

 

KY1-1104

(Zip Code)




650-808-6000
(Registrant's telephone number, including area code)




Not Applicable
(Former Name or Former Address, if changed since last report)








Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  





Item 2.02. Results of Operations and Financial Condition



On May 9, 2016, Theravance Biopharma, Inc. issued a press release and is holding a conference call regarding its financial results for the quarter ended March 31, 2016 and a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.



The information in Item 2.02 and in Item 9.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act of 1934"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits





(d) Exhibits

             99.1       Press Release dated May 09, 2016




SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.








Dated: May       09, 2016



THERAVANCE BIOPHARMA, INC.

By:  /s/ Renee D. Gala                      

     Renee D. Gala

     Senior Vice President and Chief Financial Officer







Exhibit Index



Exhibit No.
Description


99.1
Press Release dated May 09, 2016